139101-58-9

Basic information

• Product Name: 2(3H)-Benzoxazolone, 5-chloro-6-(2-chlorobenzoyl)-3-[2-(4-pyridinyl)ethyl]-
• CAS NO: 139101-58-9
• Molecular Formula: C21H14Cl2N2O3
• Molecular Weight: 413.26
• Mol File: 139101-58-9.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: 2(3H)-Benzoxazolone, 5-chloro-6-(2-chlorobenzoyl)-3-[2-(4-pyridinyl)ethyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 2(3H)-Benzoxazolone, 5-chloro-6-(2-chlorobenzoyl)-3-[2-(4-pyridinyl)ethyl]-(139101-58-9)
• EPA Substance Registry System: 2(3H)-Benzoxazolone, 5-chloro-6-(2-chlorobenzoyl)-3-[2-(4-pyridinyl)ethyl]-(139101-58-9)

Safety Data

• Hazardous Substances Data: 139101-58-9(Hazardous Substances Data)

Usage

General Description

2(3H)-Benzoxazolone, 5-chloro-6-(2-chlorobenzoyl)-3-[2-(4-pyridinyl)ethyl]- is a chemical compound with a benzoxazolone core and a chlorobenzoyl group attached to it. It also contains a pyridinyl group and an ethyl chain. 2(3H)-Benzoxazolone, 5-chloro-6-(2-chlorobenzoyl)-3-[2-(4-pyridinyl)ethyl]- may have potential applications in the pharmaceutical industry, as benzoxazolone derivatives have been studied for their antitumor, anti-inflammatory, and analgesic properties. The presence of the chloro and pyridinyl groups could also influence the compound's reactivity and biological activity, making it an interesting target for further research and exploration.

Upstream product

• 100-43-6 4-vinylpyridine 
• 95637-40-4 6-(2-chlorobenzoyl)-5-chloro-2-benzoxazolinone 

Relevant articles and documents

Synthesis of 3-(2-pyridylethyl)benzoxazolinone derivatives: Potent analgesic and antiinflammatory compounds inhibiting prostaglandin E2

Fourteen new 3-[2-(2- and/or 4-pyridyl)ethyl]benzoxazolinone derivatives have been synthesized by reacting 2- and/or 4-vinylpyridine and appropriate benzoxazolinones. Their chemical structures have been proven by IR, 1H-NMR, and elemental analysis. Analgesic activities of these compounds were investigated by a 'Modified Koster's Test'. Except for compounds 10 and 11, all the new derivatives showed higher analgesic activities than aspirin. Therefore the compounds were screened for their antiinflammatory activities using the carrageenan hind paw edema test. The compounds (6, 7, 8, 9, 14, and 17) that showed high antiinflammatory activity were then further screened for their ability to inhibit prostaglandin E2 (PGE2) induced paw edema. Although all the benzoxazolinone derivatives synthesized in this study showed higher antiinflammatory activity compared to indomethacin, those without a substituent at the 6-position of the ring were significantly more active than the rest of the group, and their ulcerogenic activities and ED50 values indicate them as promising derivatives for further study.